Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GeneDx Holdings (WGS) EBT (2020 - 2026)

GeneDx Holdings has reported EBT over the past 7 years, most recently at -$62.4 million for Q1 2026.

  • Quarterly EBT fell 926.29% to -$62.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$77.5 million through Mar 2026, down 101.81% year-over-year, with the annual reading at -$21.1 million for FY2025, 59.84% up from the prior year.
  • EBT was -$62.4 million for Q1 2026 at GeneDx Holdings, down from -$18.2 million in the prior quarter.
  • Over five years, EBT peaked at $10.6 million in Q2 2025 and troughed at -$308.7 million in Q4 2022.
  • The 5-year median for EBT is -$29.4 million (2024), against an average of -$53.6 million.
  • Year-over-year, EBT surged 135.97% in 2025 and then tumbled 926.29% in 2026.
  • A 5-year view of EBT shows it stood at -$308.7 million in 2022, then surged by 91.52% to -$26.2 million in 2023, then surged by 120.68% to $5.4 million in 2024, then tumbled by 436.72% to -$18.2 million in 2025, then crashed by 242.4% to -$62.4 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's EBT are -$62.4 million (Q1 2026), -$18.2 million (Q4 2025), and -$7.4 million (Q3 2025).